PriceTargets.com logo

Cipher Pharmaceuticals - CPH Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: C$12.50
  • Forecasted Upside: -13.31%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
C$14.42 As of 12/18/2025 04:59 PM ET
▲ +0.47 (3.37%)

This chart shows the closing price for CPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cipher Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CPH

Analyst Price Target is C$12.50
▼ -13.31% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Cipher Pharmaceuticals in the last 3 months. The average price target is C$12.50, with a high forecast of C$12.50 and a low forecast of C$12.50. The average price target represents a -13.31% upside from the last price of C$14.42.

This chart shows the closing price for CPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 investment analysts is to hold stock in Cipher Pharmaceuticals. This rating has held steady since September 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/25/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/23/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/22/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/20/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/18/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/17/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/7/2025Canaccord Genuity GroupSet TargetHoldC$12.50
11/11/2024Stifel NicolausLower TargetC$19.00 ➝ C$17.00
10/24/2024Stifel NicolausBoost TargetC$17.00 ➝ C$19.00
9/25/2024Stifel NicolausBoost TargetBuyC$16.00 ➝ C$17.00
9/13/2024Leede FinancialDowngradeStrong-Buy ➝ Hold
8/13/2024Stifel NicolausUpgradeHold ➝ BuyC$9.50 ➝ C$16.00
8/12/2024Stifel CanadaUpgradeHold ➝ Strong-Buy
5/13/2024Stifel NicolausDowngradeBuy ➝ HoldC$8.00 ➝ C$9.50
2/14/2024CitigroupBoost TargetSpeculative Buy ➝ BuyC$4.75 ➝ C$8.00
3/17/2023Leede Jones GabReiterated RatingBuy
5/13/2022Echelon Wealth PartnersReiterated RatingBuy
3/22/2021Leede Jones GabUpgradeSpeculative Buy ➝ Buy
(Data available from 12/18/2020 forward)

News Sentiment Rating

0.50 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2025
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2025
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2025

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Cipher Pharmaceuticals logo
Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.
Read More

Today's Range

Now: C$14.42
Low: C$14.08
High: C$14.60

50 Day Range

MA: C$14.34
Low: C$13.15
High: C$15.23

52 Week Range

Now: C$14.42
Low: C$10.61
High: C$17.50

Volume

33,712 shs

Average Volume

28,440 shs

Market Capitalization

C$365.84 million

P/E Ratio

21.52

Dividend Yield

N/A

Beta

0.852048

Frequently Asked Questions

What sell-side analysts currently cover shares of Cipher Pharmaceuticals?

The following sell-side analysts have issued research reports on Cipher Pharmaceuticals in the last twelve months: Canaccord Genuity Group Inc..
View the latest analyst ratings for CPH.

What is the current price target for Cipher Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Cipher Pharmaceuticals in the last year. Their average twelve-month price target is C$12.50, suggesting a possible downside of 13.3%. Canaccord Genuity Group Inc. has the highest price target set, predicting CPH will reach C$12.50 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of C$12.50 for Cipher Pharmaceuticals in the next year.
View the latest price targets for CPH.

What is the current consensus analyst rating for Cipher Pharmaceuticals?

Cipher Pharmaceuticals currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CPH, but not buy more shares or sell existing shares.
View the latest ratings for CPH.

What other companies compete with Cipher Pharmaceuticals?

Other companies that are similar to Cipher Pharmaceuticals include Hydropothecary, Canopy Growth, DRI Healthcare Trust, Knight Therapeutics and Aurora Cannabis. Learn More about companies similar to Cipher Pharmaceuticals.

How do I contact Cipher Pharmaceuticals' investor relations team?

Cipher Pharmaceuticals' physical mailing address is 2345 Argentia Rd Suite 100A, MISSISSAUGA, ON L5N 8K4, Canada. The company's listed phone number is +1-905-6025840. The official website for Cipher Pharmaceuticals is www.cipherpharma.com. Learn More about contacing Cipher Pharmaceuticals investor relations.